Summary of the Conference Call for Zhendong Pharmaceutical Industry Overview - The global adrenaline market reached $5.3 billion in 2023, with the out-of-hospital market accounting for $4.7 billion, indicating a significant demand for improved solutions due to high injection failure rates and usability issues with existing products [2][3][10]. Key Points on Zhendong Pharmaceutical - Zhendong Pharmaceutical is launching a new generation of adrenaline nasal spray with a bioavailability of 93%, significantly higher than Nefi's 31%, and is expected to fill the domestic out-of-hospital market gap [2][3][11]. - The nasal spray is anticipated to achieve sales of $54 million globally by 2025 and $494 million by 2028, showcasing the potential of the nasal spray market [2][4]. - The domestic out-of-hospital adrenaline market has a potential annual gap of $34 million, with an overall market size estimated at approximately 6-7 billion RMB [2][4]. - Zhendong has applied for independent intellectual property rights regarding the concentration and ratio of penetration enhancers, creating a technological barrier against competitors [2][10]. Market Position and Strategy - The company plans to submit IND applications in both the U.S. and China around May 2026, with clinical trials expected to begin in mid-2026 [3][12]. - Zhendong aims to capture 70% of the domestic market share for adrenaline products, projecting peak sales of 2 billion RMB despite Nefi's lead in market entry [3][15][18]. - The company’s strategy includes leveraging its technological advantages to quickly gain market share post-launch, despite Nefi's earlier market education efforts [16][17]. Competitive Advantages - Zhendong's nasal spray offers several advantages over existing products: 1. Higher bioavailability (93%) and faster absorption [5][11]. 2. Better safety profile with lower risk during repeated dosing [5]. 3. Superior storage stability at room temperature, making it more convenient than products requiring special storage [9]. 4. Lower production costs, enhancing competitive pricing [9]. Clinical Development and Future Plans - The first phase of clinical trials will focus on pharmacokinetics (PK) and safety, with a target enrollment of around 200 healthy participants [7][8]. - The company is positioned to challenge existing injection products in emergency markets, with a focus on overcoming technical barriers related to nasal drug delivery [22][29]. Financial Expectations - Zhendong anticipates a net profit of 30 million RMB in 2025, reflecting a strong outlook for its new product line [20]. Conclusion - Zhendong Pharmaceutical is strategically positioned to capitalize on the growing adrenaline market with its innovative nasal spray, backed by strong technological advantages and a clear market entry strategy. The company is set to address significant unmet needs in the out-of-hospital setting, potentially reshaping the competitive landscape in this sector [6][29].